Biesdorf, Carla http://orcid.org/0000-0002-6879-6557
Guan, Xiaowen http://orcid.org/0000-0002-2286-0920
Siddani, Satya R.
Hoffman, David
Boehm, Nils
Medeiros, Bruno C.
Doi, Toshihiko
de Jonge, Maja
Rasco, Drew
Menon, Rajeev M. http://orcid.org/0000-0002-2945-0449
Polepally, Akshanth R. http://orcid.org/0000-0002-5938-6062
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study
https://doi.org/10.1007/s00280-023-04613-9
Funding for this research was provided by:
AbbVie
Article History
Received: 25 July 2023
Accepted: 27 October 2023
First Online: 30 November 2023
Declarations
:
: Carla Biesdorf, Satya R. Siddani, David Hoffman, Nils Boehm, Bruno C. Medeiros, Rajeev M. Menon, and Akshanth R. Polepally are current employees of AbbVie Inc. and may own stock. Xiaowen Guan was an employee of AbbVie Inc. at the time of study conduct and may own stock. Toshihiko Doi is an employee of National Cancer Center Hospital East and has received research funding from Abbvie, Inc., Maja de Jonge is an employee of Erasmus Medisch Centrum and has received research funding from Abbvie, Inc., Drew Rasco is an employee of South Texas Accelerated Research Therapeutics (START) and has received research funding from Abbvie, Inc.
: The study protocol and all other study-related documents were reviewed and approved by an ethics committee/independent institutional review board (IRB) at each participating site. All subjects provided written, informed consent prior to the start of any screening or study-specific procedures. The study was conducted in accordance with the protocol, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations, and guidelines governing clinical study conduct and ethical principles that have their origin in the Declaration of Helsinki.